OptiBiotix Release: New Research Shows That Synthetic Prebiotic Boosts Growth Of Cholesterol-Reducing Bacteria In The Human Microbiome
New research from the University of Reading, Department of Food and Nutritional Sciences, and OptiBiotix Health has shown that a naturally synthesised prebiotic can selectively increase the growth of the cholesterol-reducing probiotic, Lactobacillus plantarum LPLDL®, as well as its enhancing its cholesterol-reduction activity.
This is a ground-breaking development in microbiome modulation, as it is the first time that research has demonstrated the formulation of a truly synergistic synthesised prebiotic that is capable of boosting the health benefit of a particular probiotic. The research was presented by Dr Sofia Kolida at the International Scientific Conference on Probiotics and Prebiotics (IPC) 2017 in Budapest on June 20th.
The researchers used reverse enzyme technology to synthesise a prebiotic, LPGOS, to selectively enhance the growth and cholesterol-reducing activity of the LPLDL® probiotic. LPLDL® was selected from over 4,000 other bacterial strains because of its ability to lower both cholesterol and blood pressure. In a previous study, it was found to reduce LDL cholesterol by up to 13.9%, and blood pressure by 5.1%. When combined with the LPGOS prebiotic, LPLDL® was found to increase the cholesterol lowering effect by over threefold in a 24-hour period.
This discovery indicates that a new kind of healthcare supplement may be possible: a combination of a prebiotic and a probiotic which are both targeted at the same healthcare benefit. This kind of supplement would be far more effective than existing probiotics at achieving particular health benefits. The researchers suggest that this new healthcare supplement would be called an ‘OptiBiotic’.
Dr Sofia Kolida, who presented the research at IPC 2017, commented, “Using ß-galactosidases expressed by LPLDL® (LPGOS) we achieved the synthesis of GOS modulator that works in true synergy with the parent strain, not only increasing its population but also impacting on the biological activity the probiotic was selected for. This is the first time that true synergy has been demonstrated for a synbiotic.”
The human microbiome
The human digestive tract contains a complex and diverse ecosystem of trillions of bacteria. Recently, advances in molecular and analytical techniques (metagenomics, metabolomics) have permitted identification and quantitation of species and strains of bacteria that inhabit the gastrointestinal tract, their metabolic activity, and interactions with the human host. These studies have provided greater insight into the role of gut and their metabolites in health and disease. NIH https://commonfund.nih.gov/hmp/index
Web MD http://www.webmd.com/digestive-disorders/what-your-gut-bacteria-say-your-health#1
About OptiBiotix
OptiBiotix was formed in March 2012 by Stephen O’Hara to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
www.optibiotix.com
This is a ground-breaking development in microbiome modulation, as it is the first time that research has demonstrated the formulation of a truly synergistic synthesised prebiotic that is capable of boosting the health benefit of a particular probiotic. The research was presented by Dr Sofia Kolida at the International Scientific Conference on Probiotics and Prebiotics (IPC) 2017 in Budapest on June 20th.
The researchers used reverse enzyme technology to synthesise a prebiotic, LPGOS, to selectively enhance the growth and cholesterol-reducing activity of the LPLDL® probiotic. LPLDL® was selected from over 4,000 other bacterial strains because of its ability to lower both cholesterol and blood pressure. In a previous study, it was found to reduce LDL cholesterol by up to 13.9%, and blood pressure by 5.1%. When combined with the LPGOS prebiotic, LPLDL® was found to increase the cholesterol lowering effect by over threefold in a 24-hour period.
This discovery indicates that a new kind of healthcare supplement may be possible: a combination of a prebiotic and a probiotic which are both targeted at the same healthcare benefit. This kind of supplement would be far more effective than existing probiotics at achieving particular health benefits. The researchers suggest that this new healthcare supplement would be called an ‘OptiBiotic’.
Dr Sofia Kolida, who presented the research at IPC 2017, commented, “Using ß-galactosidases expressed by LPLDL® (LPGOS) we achieved the synthesis of GOS modulator that works in true synergy with the parent strain, not only increasing its population but also impacting on the biological activity the probiotic was selected for. This is the first time that true synergy has been demonstrated for a synbiotic.”
The human microbiome
The human digestive tract contains a complex and diverse ecosystem of trillions of bacteria. Recently, advances in molecular and analytical techniques (metagenomics, metabolomics) have permitted identification and quantitation of species and strains of bacteria that inhabit the gastrointestinal tract, their metabolic activity, and interactions with the human host. These studies have provided greater insight into the role of gut and their metabolites in health and disease. NIH https://commonfund.nih.gov/hmp/index
Web MD http://www.webmd.com/digestive-disorders/what-your-gut-bacteria-say-your-health#1
About OptiBiotix
OptiBiotix was formed in March 2012 by Stephen O’Hara to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
www.optibiotix.com